Navigation Links
Alkermes Announces Positive Results from Phase 1/2 Clinical Study,of ALKS 29

Company to Proceed with Development Program for Oral Compounds to Treat Alcohol Dependence

CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 2, 2007--Alkermes, Inc. (Nasdaq: ALKS) today announced positive preliminary results from a clinical trial of ALKS 29 in alcohol dependent patients. Based on these results, the company plans to move forward with its development program for oral product candidates to treat alcohol dependence. ALKS 29 is a combination of two agents with distinct pharmacologic properties designed to provide advantages over current oral medications for the treatment of alcohol dependence. In the study, ALKS 29 was generally well tolerated and led to both a statistically significant increase in the percent of days abstinent and a decrease in drinking compared to placebo when combined with psychosocial therapy.

"We are encouraged by the positive results from this initial proof of concept study, which provide further rationale for the continued expansion of our addiction franchise," stated Elliot Ehrich, chief medical officer of Alkermes. "Addiction is an underserved disease area where a variety of treatments are needed that can improve outcomes for patients. We look forward to the complete analysis of these data, as we believe insights from this study could help pave the way for the development of ALKS 29 and other proprietary oral compounds for the treatment of alcohol dependence."

In the phase 1/2 study, patients treated with ALKS 29 demonstrated statistically significant improvement compared to placebo in terms of percent of days abstinent, percent of heavy drinking days, and average number of drinks per day. ALKS 29 was generally well tolerated during the study.

The phase 1/2 multi-center, randomized, double-blind, placebo-controlled, eight-week study was designed to assess the efficacy and safety of ALKS 29 in approximately 150 alcohol dependent patients. The study e
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/22/2008)...pment Plan Completed Successfully, DUBLIN, Irelan...ation,plc (NASDAQ: AMRN ) today announced that th...Food and Drug Administration (FDA) to discuss the,...t of,hypertriglyceridemia. Following these discuss...R101 in hypertriglyceridemia., Dr. Declan Doogan,...
(Date:7/22/2008)...and Apidra(R) Resulted in Significant, Reductions ...the Algorithm Use...ults from the "Adjust to,Target in Type 2 Diabetes...,Counting for Adjustment of Mealtime Insulin Gluli...es Association,s (ADA) medical journal,Diabetes C...
(Date:7/22/2008)...herapy and pegylated enzyme produces significan...ne - - Pegylated enzyme well tole.../ -- Halozyme Therapeutics,Inc. (Nasdaq: HALO ),...cializing products targeting the extracellular mat...pre-clinical animal efficacy data,for its pegylate...
(Date:7/22/2008)...2 /- NicOx S.A.,(Euronext P...pleted the,enrollment of 417 osteoarthritis (OA) p...al pharmacology studies in the United States, in l...als are designed to assess the,blood pressure prof...,naproxen, using the Ambulatory Blood Pressure Mon...
Breaking Medicine Technology:Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 2Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 3Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 5NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 2NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 3Mayo Researchers Say ECG Standards Should Be Revised for Elderly 14432 1Mayo Researchers Say ECG Standards Should Be Revised for Elderly 14432 2CryoCor Announces Web cast and Conference Call of 2007 Year End Results 14427 1CryoCor Announces Web cast and Conference Call of 2007 Year End Results 14427 2Obesity Linked to Poor Prognosis for Some Breast Cancer Patients 14425 1Obesity Linked to Poor Prognosis for Some Breast Cancer Patients 14425 2Obesity Linked to Poor Prognosis for Some Breast Cancer Patients 14425 3Free Egg Donor Contest Ending March 31 14421 1Free Egg Donor Contest Ending March 31 14421 2
(Date:7/25/2008)... Whether you are an Olympian, Professional ...re Five Things You Need to Know about Hydration to... and Sports Center , Mari...a,s premier athletes are heading to Beijing follow...crifice in the hopes of capturing an Olympic medal...
(Date:7/25/2008)... This donation will be used to facilitate t...es for children , Hauppau...ci.com ), a leading integrator of enterprise coll...o conferencing, telepresence, audio visual integra... today that it has donated video conferencing equi...
(Date:7/24/2008)..., N.C. Researchers at Wake Forest University Bap... clinical belief that the hepatitis C virus slows ...tself after HIV patients are treated with a combin...itis C (HCV) infection is more serious in HIV-infe...ing to the Centers for Disease Control. Intravenou...
(Date:7/24/2008)...ly 24 /PRNewswire-USNewswire/ -- Speaker Nancy Pel...in support of the Tom Lantos,and Henry J. Hyde Glo...,Malaria Reauthorization Act of 2008. The bill, wh...this evening by a vote of 303 to 115 and will now ...day the House took an historic vote to pass landma...
Breaking Medicine News(10 mins):Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 2Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 3Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 4Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 5Health News:Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 2Health News:Researchers disprove long-standing belief about HIV treatment 2Health News:Researchers disprove long-standing belief about HIV treatment 3Health News:Pelosi Statement on House Passage of Global AIDS Legislation 2
...treating tissue at the back of the mouth is succes...en and 30 per cent of women have a problem with sn...em is vibrations in the soft palate - the area of ...la, the sides of the tonsils, and the base of the ...
...ften have gastrointestinal symptoms such as incont...frequent stomach and intestinal troubles may be a ...a side effect of diabetes medications, researchers...tburn, bloating, nausea, vomiting, diarrhea and co...
...tember 11 terrorist acts in New York and Washingto...put on hold for several days, which severely affec...ceuticals. Most radiopharmaceuticals are shipped v...hese products are either radioactive themselves or...
... Administration has approved the first hormone-rel...ganon, Inc., effectively blocks conception between...that for every 100 women who use it for a year, on... That rate is similar to both the birth control pi...
Other Medicine News:
... OPMI Vario/NC33 System, Carl Zeiss has successful...et. , ,The success of this instrument is by n...ct and stylish design. Maximum ergonomic convenien...n to be used with a surgical microscope, allowing ...
...g; Suction Punch Forceps provide superior tissue e.... Shutt® Suction Graspers offer an aggressive ...he jaws. Both feature a unique stress pin bufferin...In use, the stress pin buffering system applies in...
Leg holder for arthroscopy.
Osteoprep instruments provide an array of bone shaping devices especially suited for notchplasties.
Medicine Products: